ADC Therapeutics S.A. (ADCT) has a negative trailing P/E of -3.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 87.7 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -25.58%, forward earnings yield 1.14%. PEG 0.27 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 39/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | 0.0 | 0.00 | 0.00 | 0.00 | - |
| 2017 | -19.4 | 0.00 | 7.00 | 967.84 | - |
| 2018 | -13.0 | -0.26 | 12.64 | 1,400.06 | - |
| 2019 | -17.0 | 0.71 | 17.84 | 847.33 | - |
| 2020 | -8.5 | -0.07 | 6.24 | 0.00 | - |
| 2021 | -6.7 | 0.33 | 9.33 | 45.71 | - |
| 2022 | -1.9 | 0.06 | 3.78 | 1.43 | - |
| 2023 | -0.6 | -0.01 | -0.91 | 1.95 | - |
| 2024 | -1.2 | 0.03 | -0.95 | 2.73 | - |
| 2025 | -3.1 | 0.10 | -2.41 | 5.51 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2017 | $-1.53 | $1.8M | $-89.86M | -4984% |
| 2018 | $-2.29 | $1.14M | $-123.1M | -10797.9% |
| 2019 | $-1.74 | $2.34M | $-116.48M | -4977.9% |
| 2020 | $-3.77 | $0.00 | $-246.29M | - |
| 2021 | $-3.00 | $33.92M | $-230.03M | -678.2% |
| 2022 | $-1.99 | $209.91M | $-155.8M | -74.2% |
| 2023 | $-2.94 | $69.56M | $-240.05M | -345.1% |
| 2024 | $-1.62 | $69.28M | $-157.85M | -227.8% |
| 2025 | $-1.12 | $81.36M | $-142.62M | -175.3% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.80 | $-0.92 – $-0.68 | $79.96M | $73.13M – $86.02M | 4 |
| 2027 | $-0.64 | $-0.85 – $-0.26 | $133.29M | $117.19M – $146.58M | 5 |
| 2028 | $0.04 | $-0.65 – $0.62 | $278.48M | $254.71M – $299.61M | 4 |
| 2029 | $0.60 | $0.54 – $0.66 | $405.98M | $371.33M – $436.78M | 2 |
| 2030 | $0.82 | $0.73 – $0.90 | $458.28M | $419.16M – $493.05M | 2 |
